Literature DB >> 22566668

Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs.

Elena Grossini1, Claudio Molinari, Piero Pollesello, Giorgio Bellomo, Guido Valente, David Mary, Giovanni Vacca, Philippe Caimmi.   

Abstract

Ischemia/reperfusion (I/R) injury is an important cause of acute renal failure because of oxidative, inflammatory, and apoptotic mechanisms. The aim of the present study was to examine any possible protective effects of levosimendan in an in vivo pig model of renal I/R injury. In 40 anesthetized pigs (eight groups of five pigs each), I/R was induced by clamping-reopening the left renal artery. During ischemia, in three groups of pigs, levosimendan and the multiorgan preservation solution Custodiol, alone or in combination with levosimendan, were infused in the renal artery. In two other groups of animals, levosimendan in combination with Custodiol was administered after the intrarenal nitric-oxide (NO) synthase blocker N(ω)-nitro-L-arginine methyl ester (L-NAME) or the mitochondrial ATP-sensitive K(+) channel (K(ATP) channel) inhibitor 5-hydroxydecanoate (5-HD). In the other animals, saline, L-NAME, or 5-HD were administered alone. Throughout the experiments, urinary N-acetyl-β-glucosaminidase (NAG) release was measured, and renal function was assessed. Moreover, renal biopsy samples were taken for the detection of apoptosis and tissue peroxidation. In pigs treated with levosimendan or the combination of levosimendan and Custodiol, NAG, peroxidation, and apoptotic markers were lower than in animals treated with Custodiol alone. In addition, renal function was better preserved, and cell survival and antioxidant systems were more activated. All beneficial effects were prevented by L-NAME and 5-HD. In conclusion, levosimendan alone or in combination with Custodiol exerted better protection against renal I/R injuries than Custodiol alone through antioxidant, antiapoptotic, and prosurvival actions depending on mitochondrial K(ATP) channels and NO-related mechanisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22566668     DOI: 10.1124/jpet.112.193961

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

1.  Assessment of the Nephroprotective Properties of the Erythropoietin Mimetic Peptide and Infliximab in Kidney Ischemia-Reperfusion Injury in Rats.

Authors:  A S Netrebenko; V V Gureev; M V Pokrovskii; A V Gureeva; Y M Tsuverkalova; I S Rozhkov
Journal:  Arch Razi Inst       Date:  2021-10-31

2.  Effects of Levosimendan on Systemic Perfusion in Patients with Low Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Score: Experience from a Single Center in Taiwan.

Authors:  Ying-Hsiang Wang; Jia-Lin Chen; Chien-Sung Tsai; Yi-Ting Tsai; Chih-Yuan Lin; Hong-Yan Ke; Po-Shun Hsu
Journal:  Acta Cardiol Sin       Date:  2021-09       Impact factor: 2.672

3.  Tanshinone IIA pretreatment attenuates ischemia/reperfusion-induced renal injury.

Authors:  Yan-Mei Xu; Guo-Hua Ding; Jie Huang; Yan Xiong
Journal:  Exp Ther Med       Date:  2016-09-06       Impact factor: 2.447

4.  Cell injury after ischemia and reperfusion in the porcine kidney evaluated by radiolabelled microspheres, sestamibi, and lactadherin.

Authors:  Stine S Pedersen; Anna K Keller; Marie K Nielsen; Bente Jespersen; Lise Falborg; Jan T Rasmussen; Christian W Heegaard; Michael Rehling
Journal:  EJNMMI Res       Date:  2013-08-07       Impact factor: 3.138

5.  Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials.

Authors:  Tiziana Bove; Andrea Matteazzi; Alessandro Belletti; Gianluca Paternoster; Omar Saleh; Daiana Taddeo; Roberto Dossi; Teresa Greco; Nikola Bradic; Ino Husedzinovic; Caetano Nigro Neto; Vladimir V Lomivorotov; Maria Grazia Calabrò
Journal:  Heart Lung Vessel       Date:  2015

6.  Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay.

Authors:  Elena Grossini; Kevin Bellofatto; Serena Farruggio; Lorenzo Sigaudo; Patrizia Marotta; Giulia Raina; Veronica De Giuli; David Mary; Piero Pollesello; Rosalba Minisini; Mario Pirisi; Giovanni Vacca
Journal:  PLoS One       Date:  2015-04-16       Impact factor: 3.240

Review 7.  Renal ischemia/reperfusion injury; from pathophysiology to treatment.

Authors:  Maryam Malek; Mehdi Nematbakhsh
Journal:  J Renal Inj Prev       Date:  2015-06-01

8.  Levosimendan increases brain tissue oxygen levels after cardiopulmonary resuscitation independent of cardiac function and cerebral perfusion.

Authors:  Andreas García-Bardon; Jens Kamuf; Alexander Ziebart; Tanghua Liu; Nadia Krebs; Bastian Dünges; Robert F Kelm; Svenja Morsbach; Kristin Mohr; Axel Heimann; Erik K Hartmann; Serge C Thal
Journal:  Sci Rep       Date:  2021-07-09       Impact factor: 4.379

9.  Levosimendan: a cardiovascular drug to prevent liver ischemia-reperfusion injury?

Authors:  Peter Onody; Rita Stangl; Andras Fulop; Oliver Rosero; David Garbaisz; Zsolt Turoczi; Gabor Lotz; Zoltan Rakonczay; Zsolt Balla; Viktor Hegedus; Laszlo Harsanyi; Attila Szijarto
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

Review 10.  Renal effects of levosimendan: a consensus report.

Authors:  Mehmet B Yilmaz; Elena Grossini; José C Silva Cardoso; István Édes; Francesco Fedele; Piero Pollesello; Matti Kivikko; Veli-Pekka Harjola; Julia Hasslacher; Alexandre Mebazaa; Andrea Morelli; Jos le Noble; Anders Oldner; Ignacio Oulego Erroz; John T Parissis; Alexander Parkhomenko; Gerhard Poelzl; Sebastian Rehberg; Sven-Erik Ricksten; Luís M Rodríguez Fernández; Markku Salmenperä; Mervyn Singer; Sascha Treskatsch; Bojan Vrtovec; Gerhard Wikström
Journal:  Cardiovasc Drugs Ther       Date:  2013-12       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.